首页 | 本学科首页   官方微博 | 高级检索  
检索        

门脉局部注入DDPH治疗大鼠肝硬化门脉高压的实验研究
引用本文:吴汉平,冯敢生,梁惠民,郑传胜.门脉局部注入DDPH治疗大鼠肝硬化门脉高压的实验研究[J].华中科技大学学报(医学版),2003,32(2):166-170.
作者姓名:吴汉平  冯敢生  梁惠民  郑传胜
作者单位:华中科技大学同济医学院附属协和医院介入放射科,武汉,430022
基金项目:卫生部科学基金资助项目 (No:98- 1- 132 )
摘    要:目的 研究l—(2,6—二甲基苯氧基)—2—(3,4—二甲氧基苯乙氨基)丙烷盐酸盐(DDPH)对实验性大鼠肝硬化门脉高压症的治疗作用,探讨合适的药物及给药途径。方法 在CCl4诱发的大鼠肝硬化门脉高压模型上,分别经下腔静脉或门静脉注入哌唑嗪(PRZ),维拉帕米(VER)和DDPH,测量门静脉压(PVP)、下腔静脉压(ICVP)、平均动脉压(MAP)和心率(HR),比较两种给药途径对门脉和全身血流动力学影响的特点,并观察DDPH对肝纤维化的防治作用。结果 门脉注入DDPH使PVP、MAP下降,并呈剂量依赖性,PRZ随剂量增加降PVP、MAP作用呈逐渐减弱的趋势,VER降PVP、MAP作用最弱,减慢HR作用最强。DDPH门脉给药后PVP下降,50min时仍无明显恢复,其它2种药物停止注药后PVP开始恢复,50min时降压作用基本消失;3种药物门脉给药降PVP作用明显强于下腔静脉给药,降MAP作用则明显弱于后者,对HR影响均较小;DDPH可以减轻CCl4对肝细胞的损害和肝纤维化的程度。结论 DDPH是理想的治疗肝硬化门脉高压症的扩血管药物,门脉是扩血管药物治疗门脉高压症的理想途径。

关 键 词:肝硬化  门脉高压  治疗  l-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐  DDPH  给药途径
修稿时间:2001年11月29

Experimental Study of DDPH Intraportal Injection Treating Portal Hypertension Associated with Liver Cirrhosis in Rats
Wu Hanping,Feng Gansheng,Liang Huimin et al.Experimental Study of DDPH Intraportal Injection Treating Portal Hypertension Associated with Liver Cirrhosis in Rats[J].Journal of Huazhong University of Science and Technology(Health Sciences),2003,32(2):166-170.
Authors:Wu Hanping  Feng Gansheng  Liang Huimin
Institution:Wu Hanping,Feng Gansheng,Liang Huimin et al Department of Interventional Radiology,Xiehe Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022
Abstract:Objective To study the effects of DDPH portal vein administration in the treatment of portal hypertension associated with liver cirrhosis on animal models and to find out the ideal route and drugs for portal hypertension treatment. Methods Portal hypertension rats with liver cirrhosis induced by CCl 4 were used in this study. Prazosin (PRZ), verapamil (VER) and 1 (2,6 dimethylphenoxy) 2 (3,4 dime thoxyphenylamino) propane hydrochloride (DDPH) were injected into inferior caval vein or portal vein. The changes of portal vein pressure (PVP), inferior caval vein pressure (ICVP), mean artery pressure (MAP) and heart rate (HR) for each drug were compared. The preventive effect of DDPH on liver cirrhosis was observed. Results DDPH portal vein administration could decrease PVP and MAP in a dose dependent manner. PRZ could decrease PVP and MAP, but not dose dependently. VER changed PVP and MAP less, but decreased HR significantly. DDPH intraportal injection kept PVP dropping much longer than other 2 drugs did. The portal vein injection of three drugs decreased PVP more significantly and affected MAP and HR less than inferior caval vein infusion. DDPH could attenuate hepatic cells damage and liver cirrhosis induced by CCl 4 . Conclusion Intraportal injection is an ideal route for vasodilators treating portal hypertension. DDPH is an ideal drug for intraportal administration treating portal hypertension.
Keywords:hypertension  portal  liver cirrhosis  administration route  portal vein  1 (2  6  dimethylphenoxy)  2  (3  4  dime  thoxyphenylamino) propane hydrochloride
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号